S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
NASDAQ:ALGS

Aligos Therapeutics - ALGS Stock Forecast, Price & News

$1.32
0.00 (0.00%)
(As of 03/17/2023 06:55 PM ET)
Add
Compare
Today's Range
$1.23
$1.35
50-Day Range
$1.30
$2.11
52-Week Range
$0.84
$2.99
Volume
124,300 shs
Average Volume
434,115 shs
Market Capitalization
$56.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Aligos Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
203.0% Upside
$4.00 Price Target
Short Interest
Healthy
2.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.75) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

309th out of 983 stocks

Biological Products, Except Diagnostic Industry

51st out of 161 stocks


ALGS stock logo

About Aligos Therapeutics (NASDAQ:ALGS) Stock

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALGS Stock News Headlines

Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
ALGS Aligos Therapeutics, Inc.
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
SVB Securities Sticks to Its Hold Rating for Aligos Therapeutics (ALGS)
See More Headlines
Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALGS Company Calendar

Last Earnings
11/03/2021
Today
3/20/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALGS
Fax
N/A
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+203.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-96,050,000.00
Net Margins
-690.63%
Pretax Margin
-689.87%

Debt

Sales & Book Value

Annual Sales
$13.91 million
Book Value
$2.43 per share

Miscellaneous

Free Float
36,585,000
Market Cap
$56.68 million
Optionable
Not Optionable
Beta
2.50

Key Executives

  • Dr. Lawrence M. Blatt MBA (Age 60)
    Ph.D., CEO & Chairman
    Comp: $872.58k
  • Dr. Leonid Beigelman Ph.D. (Age 63)
    Pres & Director
    Comp: $702.25k
  • Dr. Julian A. Symons DPHIL (Age 61)
    Exec. VP & Chief Scientific Officer
    Comp: $618.82k
  • Ms. Lesley Ann Calhoun CPA (Age 56)
    Exec. VP & CFO
  • Ms. Lucinda Y. Quan J.D. (Age 50)
    Exec. VP, Chief Bus. Officer & Gen. Counsel
  • Kristina Engeseth
    Exec. Director and Head of People & Culture
  • Mr. John Fry (Age 59)
    Exec. VP of Clinical Devel.
  • Dr. Matthew W. McClure M.D. (Age 50)
    Exec. VP & Chief Medical Officer
  • Dr. Sushmita M. Chanda DABT (Age 56)
    Ph.D., Exec. VP of Translational Safety Sciences
  • Dr. David B. Smith Ph.D.
    Exec. VP & Head of Chemical Operations













ALGS Stock - Frequently Asked Questions

Should I buy or sell Aligos Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALGS shares.
View ALGS analyst ratings
or view top-rated stocks.

What is Aligos Therapeutics' stock price forecast for 2023?

4 brokers have issued 1-year price targets for Aligos Therapeutics' shares. Their ALGS share price forecasts range from $2.00 to $7.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price.
View analysts price targets for ALGS
or view top-rated stocks among Wall Street analysts.

How have ALGS shares performed in 2023?

Aligos Therapeutics' stock was trading at $0.9529 at the beginning of the year. Since then, ALGS shares have increased by 38.5% and is now trading at $1.32.
View the best growth stocks for 2023 here
.

Are investors shorting Aligos Therapeutics?

Aligos Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 853,900 shares, an increase of 16.2% from the February 13th total of 735,100 shares. Based on an average trading volume of 402,600 shares, the days-to-cover ratio is presently 2.1 days. Approximately 2.9% of the shares of the stock are sold short.
View Aligos Therapeutics' Short Interest
.

When is Aligos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ALGS earnings forecast
.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.03. The business had revenue of $1.54 million for the quarter. Aligos Therapeutics had a negative net margin of 690.63% and a negative trailing twelve-month return on equity of 74.49%.

When did Aligos Therapeutics IPO?

(ALGS) raised $150 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

What is Aligos Therapeutics' stock symbol?

Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS."

Who are Aligos Therapeutics' major shareholders?

Aligos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (6.58%), Point72 Asset Management L.P. (2.12%), Renaissance Technologies LLC (1.24%), Millennium Management LLC (0.87%), New York Life Investment Management LLC (0.62%) and Geode Capital Management LLC (0.47%). Insiders that own company stock include Thomas Woiwode and Vivo Capital Fund Viii, LP.
View institutional ownership trends
.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aligos Therapeutics' stock price today?

One share of ALGS stock can currently be purchased for approximately $1.32.

How much money does Aligos Therapeutics make?

Aligos Therapeutics (NASDAQ:ALGS) has a market capitalization of $56.68 million and generates $13.91 million in revenue each year. The company earns $-96,050,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

How can I contact Aligos Therapeutics?

The official website for the company is www.aligos.com. The company can be reached via phone at 800-466-6059 or via email at cdavis@lifesciadvisors.com.

This page (NASDAQ:ALGS) was last updated on 3/20/2023 by MarketBeat.com Staff